Eli Lilly and Company (NYSE:LLY) Reaches New 1-Year High – Time to Buy?

Shares of Eli Lilly and Company (NYSE:LLY) reached a new 52-week high on Tuesday. The stock traded as high as $1,304.31 and last traded at $1,300.4580, with a volume of 817,801 shares. The stock had previously closed at $1,240.34.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: GLP-1 growth remains the primary catalyst. Analysts expect Mounjaro, Zepbound and the oral GLP-1 treatment Foundayo to support upcoming third-quarter results. Bank of America expects Foundayo to continue gaining market share over the next year, while Lilly’s growth and improving margins could help justify its premium valuation. How will Eli Lilly’s GLP-1 portfolio sales aid upcoming Q3 results?
• Positive Sentiment: Omvoh produced encouraging pediatric ulcerative-colitis data. In the Phase 3 SHINE-2 study, 81% of patients achieved a clinical response after induction, and 50% of responders reached clinical remission at one year. Lilly plans to submit the data to regulators for a potential label expansion, adding to the company’s longer-term revenue diversification. Lilly’s Omvoh pediatric ulcerative-colitis study
• Positive Sentiment: Pipeline and partnership news support future growth. Lilly will present oncology data at the 2026 ESMO Congress and agreed to pay Metis TechBio up to $1.1 billion for AI-enabled drug-delivery technology, potentially strengthening future development capabilities. Metis TechBio deal with Eli Lilly
• Neutral Sentiment: Relative strength is attracting investors. Lilly has outperformed broader indexes over recent months and is trading close to its high, benefiting from defensive demand as technology and AI stocks weaken. RBC also issued a Buy rating, although the stock’s elevated earnings multiple leaves less room for disappointment. RBC Buy rating
• Negative Sentiment: Competitive and legal risks are limiting enthusiasm. A potential weight-loss drug price war with Novo Nordisk, concentrated dependence on GLP-1 products and Lilly’s premium valuation could pressure the shares. Separately, a Pennsylvania lawsuit alleges insulin-price inflation exceeding 1,000%; the claims remain unproven but add headline and regulatory risk. Eli Lilly insulin pricing lawsuit

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. UBS Group set a $1,376.00 target price on Eli Lilly and Company in a report on Friday, August 7th. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research note on Thursday, September 17th. Leerink Partners upped their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. TD Cowen restated a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Finally, Guggenheim increased their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Stock Up 4.9%

The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.22 trillion, a P/E ratio of 43.59, a PEG ratio of 1.67 and a beta of 0.46. The firm has a 50-day moving average price of $1,180.34 and a two-hundred day moving average price of $1,111.84.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the previous year, the firm posted $6.31 EPS. The business’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 33.56 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LLY. Integrity Financial Corp WA grew its position in Eli Lilly and Company by 1.3% during the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after purchasing an additional 8 shares in the last quarter. Willner & Heller LLC grew its holdings in shares of Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after buying an additional 9 shares in the last quarter. Aspiring Ventures LLC grew its holdings in shares of Eli Lilly and Company by 3.7% during the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after buying an additional 9 shares in the last quarter. Wealthspan Partners LLC grew its stake in Eli Lilly and Company by 0.4% during the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after acquiring an additional 9 shares in the last quarter. Finally, Navigoe LLC grew its position in Eli Lilly and Company by 8.7% during the second quarter. Navigoe LLC now owns 113 shares of the company’s stock valued at $135,000 after purchasing an additional 9 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.